Sign in Subscribe
Class action lawsuits

Securities Class Action Lawsuit Filed Against Alto Neuroscience, Inc.

Strategic Insights

— 1 min read

Investors in Alto Neuroscience, Inc. may be affected by alleged securities fraud, and a class action lawsuit seeks to recover losses on their behalf. The lawsuit concerns investors who purchased Alto common stock in connection with the company's initial public offering on February 2, 2024, or acquired the company's securities between February 2, 2024, and October 22, 2024. The complaint alleges that the company's product pipeline, ALTO-100, was less effective in treating major depressive disorder than investors were led to believe, and the company's public statements were materially false and misleading.

Key Takeaways:

  • The lawsuit covers investors who purchased Alto common stock in the initial public offering on February 2, 2024, or acquired the company's securities between February 2, 2024, and October 22, 2024.
  • The complaint alleges that Alto's product pipeline, ALTO-100, was less effective in treating major depressive disorder than investors were led to believe.
  • The company's public statements were allegedly materially false and misleading.
  • The lawsuit seeks to recover losses on behalf of affected investors.
  • Alto Neuroscience, Inc. is a publicly traded company listed on the NYSE under the ticker symbol ANRO.
  • The complaint alleges that Alto's business and financial prospects were overstated due to the company's alleged misrepresentations about its product pipeline.

Statistics:

  • The lawsuit seeks to recover losses on behalf of a class consisting of all persons and entities that purchased or otherwise acquired Alto common stock between February 2, 2024, and October 22, 2024.
  • The complaint alleges that Alto's product pipeline, ALTO-100, was less effective in treating major depressive disorder than investors were led to believe.
  • The lawsuit alleges that Alto's public statements were materially false and misleading from February 2, 2024, to October 22, 2024.
  • The deadline to request that the Court appoint a lead plaintiff is September 19, 2025.

Sources:

  • Press release from Levi & Korsinsky, LLP, "Alto Neuroscience, Inc. (ANRO) Breach of Fiduciary Duty and Securities Lawsuit - LEVI & KORSINSKY, LLP NOTIFIES INVESTORS OF CLASS ACTION LAWSUIT" (August 12, 2025)
  • Source: An announced link to the source material

Read more